AI assistant
GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2015
Aug 27, 2015
65022_rns_2015-08-27_2e104506-2c09-4e2e-97df-4244c4e2e4bb.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [595 x 68] intentionally omitted <==
==> picture [595 x 68] intentionally omitted <==
ASX ANNOUNCEMENT
28 August 2015
Lapse of Share Options
Melbourne, Australia, 28 August 2015: Genetic Technologies Limited advises that 10,150,000 unlisted share options granted pursuant to the Company’s employee option plan have lapsed. The details of these lapsed options are:
| s of these lapsed options are: | ||
|---|---|---|
| Unlisted employee option reference | Exercise price | Options lapsed |
| GTGAO (expiring 29 August 2017) | $0.14 | 2,400,000 |
| GTGAA (expiring 31 May 2019) | $0.04 | 5,500,000 |
| GTGAQ (expiring 1 December 2017) | $0.10 | 250,000 |
| GTGAS (expiring 25 January 2018) | $0.10 | 500,000 |
| GTGAK (expiring 20 February 2017) | $0.12 | 500,000 |
| GTGAW (expiring 31 March 2016) | $0.19 | 500,000 |
| GTGAY (expiring 11 July 2018) | $0.105 | 500,000 |
| Total | 10,150,000 |
Accordingly, as at the date of this announcement, as summarises below, there are a total of 24,241,667 outstanding options over shares in the Company.
| Unlisted employee options | ||
|---|---|---|
| GTGAM (expiring 31 July 2016) | $0.20 | 1,000,000 |
| GTGAO (expiring 29 August 2017) | $0.14 | 250,000 |
| GTGAW (expiring 31 March 2016) | $0.19 | 1,250,000 |
| GTGAY (expiring 11 July 2018) | $0.105 | 250,000 |
| GTGAA (expiring 31 May 2019) | $0.04 | 1,125,000 |
| Unlisted options attached to convertiblenotes | ||
| GTGAC (expiring 2 December 2018) | $0.015 | 20,366,667 |
| Ttl | 24241667 | |
| oa | ,, |
Genetic Technologies Limited • Website : www.gtglabs.com • Email : [email protected] ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040
==> picture [595 x 68] intentionally omitted <==
==> picture [595 x 68] intentionally omitted <==
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli Executive Director & Chief Executive Officer Genetic Technologies Limited + 61 3 8412 7050
Candice Knoll (USA) Blueprint Life Science Group +1 (415) 375 3340, Ext. 105
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product, BREVAGen plus ®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGen plus ® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGen plus ® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGen plus ®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGen plus ® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
Genetic Technologies Limited • Website : www.gtglabs.com • Email : [email protected] ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040